莫西沙星与阿米卡星化疗方案对耐药肺结核患者痰阴转率的影响对比

Comparison of the Effect of Moxifloxacin and Amikacin Chemotherapy on Sputum Negative Conversion Rate of Drug-resistant Tuberculosis Patients

目的探讨莫西沙星与阿米卡星化疗方案对耐药肺结核患者痰阴转率的影响。方法选取于2015年5月—2020年1月期间在河南科技大学第一附属医院就诊的100例耐药肺结核患者,按随机数表方法分为对照组50例,观察组50例。所有患者均采用化疗治疗,对照组加用阿米卡星治疗,观察组加用莫西沙星治疗。比较两组患者治疗后痰涂片转阴、空洞闭合和不良反应。结果治疗后,观察组痰涂片转阴、空洞闭合率均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论相比阿米卡星治疗,针对耐药肺结核患者采用莫西沙星治疗,有利于提高痰阴转率,促进空洞闭合,且不良反应较轻,值得临床推广。

Objective To investigate the effect of moxifloxacin and amikacin chemotherapy on sputum negative conversion rate of drug-resistant tuberculosis patients.Methods 100 patients with drug-resistant tuberculosis in the hospital from May,2015 to January,2020 were selected and divided into control group(50 cases)and observation group(50 cases).All patients were treated with chemotherapy.Based on this,control group received amikacin,and observation group received moxifloxacin.The sputum smear negative,cavity closure and adverse reactions were compared between the two groups.Results After treatment,the rate of sputum smear turning negative and cavity closing in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions of two groups(P>0.05).Conclusion Compared with amikacin treatment,moxifloxacin treatment for drug-resistant pulmonary tuberculosis is beneficial to improve the rate of sputum negative conversion,and promote the closure of cavity.It has less adverse reactions,which is worthy of clinical promotion.